- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/327 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 207/327
Total number of patents in this class: 99
10-year publication summary
|
5
|
9
|
4
|
10
|
4
|
4
|
7
|
8
|
4
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vectus Biosystems Limited | 29 |
6 |
| The Wistar Institute of Anatomy and Biology | 484 |
4 |
| Rhizen Pharmaceuticals AG | 57 |
4 |
| Duke University | 3184 |
3 |
| Iowa State University Research Foundation, Inc. | 825 |
3 |
| Taisho Pharmaceutical Co., Ltd. | 851 |
3 |
| Toyama Chemical Co., Ltd. | 89 |
3 |
| The University of North Carolina at Chapel Hill | 2093 |
3 |
| Laurel Therapeutics Ltd. | 6 |
3 |
| Bristol-myers Squibb Company | 4729 |
2 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
2 |
| Hangzhou DAC Biotech Co., Ltd | 113 |
2 |
| King Abdullah University of Science and Technology | 1848 |
2 |
| Ligand Pharmaceuticals Incorporated | 167 |
2 |
| National University Corporation Hokkaido University | 1366 |
2 |
| Oregon Health & Science University | 755 |
2 |
| Turn Biotechnologies Inc. | 21 |
2 |
| Shanghaitech University | 390 |
2 |
| Grey Wolf Therapeutics Limited | 17 |
2 |
| Infex Therapeutics Limited | 18 |
2 |
| Other owners | 45 |